We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
A Preview of Coca-Cola European Partners' (CCE) Q1 Earnings
Read MoreHide Full Article
Coca-Cola European Partners plc or CCEP is set to report first-quarter 2018 results, before the opening bell on Apr 26.
In the last reported quarter, the company delivered a positive earnings surprise of 5.45%. The company surpassed/met the Zacks Consensus Estimate for earnings in the trailing four quarters, the average beat being 6.88%.
Factors at Play
In 2017, CCEP modestly exceeded its initial guidance for revenue, operating profit, earnings per share and free cash flow. The company’s continuous focus on brand and packaging innovation, solid revenue per unit case growth (up 200% year over year) in sugar-free portfolio, stronger execution and customer service, and improving operating efficiency helped drive growth.
This has encouraged CCEP to step up investments in brand portfolio, field sales teams, route to market and most importantly, digital capabilities.
In the last reported quarter, the company’s net sales increased 12.7% year over year in dollar terms. Comparable revenues in the quarter grew 3.5%. From a brand and volume perspective, CCEP’s sparkling portfolio increased 1%, with a 0.5% drop in Coca-Cola trademark brands. Notably, Coca-Cola Zero Sugar continued to perform well, growing more than 15%. Again, energy drinks performed well and were up 15% as the company continued to execute its multi-brand strategy.
Apart from solid revenues, the company’s cost-saving plans are helping boost the bottom line. In the fourth quarter, operating expenses contracted 11.5% on a comparable and currency neutral basis. This reflects synergy benefits, volume-related costs, expense timing and continued focus on managing operating expenses. These factors contributed to operating profit growth of 50% on a comparable and currency neutral basis. Comparable earnings jumped 26.1% year over year in the quarter.
We expect the growth momentum to continue in the to-be-reported quarter as well. Importantly, CCEP is on track to achieve pre-tax synergy savings of €315-€340 million by mid-2019.
Overall, for the first quarter, the Zacks Consensus Estimate for earnings is pegged at 39 cents, reflecting a 18.2% year-over-year increase. The consensus estimate for revenues is $3 billion, implying a 19.1% increase.
Here’s What Our Quantitative Model Predicts:
CCEP does not have the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or higher — which increases the odds of an earnings beat.
Zacks ESP: The Earnings ESP for CCEP is 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Meanwhile, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is witnessing negative estimate revisions.
Coca-Cola European Partners PLC Price and EPS Surprise
The Coca-Cola Company (KO - Free Report) started off 2018 on a strong note, beating the Zacks Consensus Estimate for both the counts in first-quarter 2018.
Upcoming Peer Releases
PepsiCo, Inc. (PEP - Free Report) is scheduled to report quarterly results on Apr 26.
Monster Beverage Corp. (MNST - Free Report) is expected to report quarterly results on May 3.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
A Preview of Coca-Cola European Partners' (CCE) Q1 Earnings
Coca-Cola European Partners plc or CCEP is set to report first-quarter 2018 results, before the opening bell on Apr 26.
In the last reported quarter, the company delivered a positive earnings surprise of 5.45%. The company surpassed/met the Zacks Consensus Estimate for earnings in the trailing four quarters, the average beat being 6.88%.
Factors at Play
In 2017, CCEP modestly exceeded its initial guidance for revenue, operating profit, earnings per share and free cash flow. The company’s continuous focus on brand and packaging innovation, solid revenue per unit case growth (up 200% year over year) in sugar-free portfolio, stronger execution and customer service, and improving operating efficiency helped drive growth.
This has encouraged CCEP to step up investments in brand portfolio, field sales teams, route to market and most importantly, digital capabilities.
In the last reported quarter, the company’s net sales increased 12.7% year over year in dollar terms. Comparable revenues in the quarter grew 3.5%. From a brand and volume perspective, CCEP’s sparkling portfolio increased 1%, with a 0.5% drop in Coca-Cola trademark brands. Notably, Coca-Cola Zero Sugar continued to perform well, growing more than 15%. Again, energy drinks performed well and were up 15% as the company continued to execute its multi-brand strategy.
Apart from solid revenues, the company’s cost-saving plans are helping boost the bottom line. In the fourth quarter, operating expenses contracted 11.5% on a comparable and currency neutral basis. This reflects synergy benefits, volume-related costs, expense timing and continued focus on managing operating expenses. These factors contributed to operating profit growth of 50% on a comparable and currency neutral basis. Comparable earnings jumped 26.1% year over year in the quarter.
We expect the growth momentum to continue in the to-be-reported quarter as well. Importantly, CCEP is on track to achieve pre-tax synergy savings of €315-€340 million by mid-2019.
Overall, for the first quarter, the Zacks Consensus Estimate for earnings is pegged at 39 cents, reflecting a 18.2% year-over-year increase. The consensus estimate for revenues is $3 billion, implying a 19.1% increase.
Here’s What Our Quantitative Model Predicts:
CCEP does not have the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or higher — which increases the odds of an earnings beat.
Zacks ESP: The Earnings ESP for CCEP is 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: CCEP carries a Zacks Rank #3, which increases the predictive power of ESP. However, an ESP of 0.00% makes earnings prediction difficult. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Meanwhile, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is witnessing negative estimate revisions.
Coca-Cola European Partners PLC Price and EPS Surprise
Coca-Cola European Partners PLC Price and EPS Surprise | Coca-Cola European Partners PLC Quote
Peer Release
The Coca-Cola Company (KO - Free Report) started off 2018 on a strong note, beating the Zacks Consensus Estimate for both the counts in first-quarter 2018.
Upcoming Peer Releases
PepsiCo, Inc. (PEP - Free Report) is scheduled to report quarterly results on Apr 26.
Monster Beverage Corp. (MNST - Free Report) is expected to report quarterly results on May 3.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them>>